CRY Cardiovascular Pathology Unit, Cardiovascular Clinical Academic Group, Molecular and Clinical Sciences Research Institute, St. George's, University of London, London, UK.
Department of Pathology, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands.
Virchows Arch. 2023 Apr;482(4):653-669. doi: 10.1007/s00428-023-03523-8. Epub 2023 Mar 10.
Cardiomyopathies (CMP) comprise a heterogenous group of diseases affecting primarily the myocardium, either genetic and/or acquired in origin. While many classification systems have been proposed in the clinical setting, there is no internationally agreed pathological consensus concerning the diagnostic approach to inherited CMP at autopsy. A document on autopsy diagnosis of CMP is needed because the complexity of the pathologic backgrounds requires proper insight and expertise. In cases presenting with cardiac hypertrophy and/or dilatation/scarring with normal coronary arteries, a suspicion of inherited CMP must be considered, and a histological examination is essential. Establishing the actual cause of the disease may require a number of tissue-based and/or fluid-based investigations, be it histological, ultrastructural, or molecular. A history of illicit drug use must be looked for. Sudden death is frequently the first manifestation of disease in case of CMP, especially in the young. Also, during routine clinical or forensic autopsies, a suspicion of CMP may arise based on clinical data or pathological findings at autopsy. It is thus a challenge to make a diagnosis of a CMP at autopsy. The pathology report should provide the relevant data and a cardiac diagnosis which can help the family in furthering investigations, including genetic testing in case of genetic forms of CMP. With the explosion in molecular testing and the concept of the molecular autopsy, the pathologist should use strict criteria in the diagnosis of CMP, and helpful for clinical geneticists and cardiologists who advise the family as to the possibility of a genetic disease.
心肌病(CMP)是一组主要影响心肌的异质性疾病,其病因既有遗传性的,也有获得性的。尽管在临床环境中已经提出了许多分类系统,但在尸检中诊断遗传性 CMP 方面尚无国际公认的病理共识。由于病理背景的复杂性需要适当的洞察力和专业知识,因此需要一份关于尸检诊断 CMP 的文件。在出现心脏肥大和/或扩张/瘢痕形成且冠状动脉正常的情况下,必须怀疑遗传性 CMP,并进行组织学检查。确定疾病的实际原因可能需要进行一些基于组织和/或液体的检查,无论是组织学、超微结构还是分子学检查。必须寻找非法药物使用的病史。在 CMP 的情况下,猝死通常是疾病的第一个表现,尤其是在年轻人中。此外,在常规临床或法医尸检中,根据临床数据或尸检中的病理发现,可能会怀疑存在 CMP。因此,在尸检中诊断 CMP 是一项挑战。病理报告应提供相关数据和心脏诊断,这可以帮助家属进一步进行调查,包括遗传性 CMP 的基因检测。随着分子检测的爆炸式增长和分子尸检的概念,病理学家应在 CMP 的诊断中使用严格的标准,这对为家属提供遗传疾病可能性建议的临床遗传学家和心脏病学家也有帮助。